Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects
Clinical trial NCT00841646 · COMPLETED
Trial details
- NCT number
- NCT00841646
- Sponsor
- Novartis Vaccines
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-12-01
- Primary completion
- 2009-07-01
- Enrollment
- 343
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.